MA43753A - Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu - Google Patents
Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbuInfo
- Publication number
- MA43753A MA43753A MA043753A MA43753A MA43753A MA 43753 A MA43753 A MA 43753A MA 043753 A MA043753 A MA 043753A MA 43753 A MA43753 A MA 43753A MA 43753 A MA43753 A MA 43753A
- Authority
- MA
- Morocco
- Prior art keywords
- dbu
- cyano
- inhibitors
- pyrrolidine derivatives
- pyrrolidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1605059.3A GB201605059D0 (en) | 2016-03-24 | 2016-03-24 | Novel compounds |
| GBGB1700839.2A GB201700839D0 (en) | 2017-01-18 | 2017-01-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43753A true MA43753A (fr) | 2018-11-28 |
Family
ID=58455357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043753A MA43753A (fr) | 2016-03-24 | 2017-03-23 | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11352339B2 (fr) |
| EP (1) | EP3433246B1 (fr) |
| JP (1) | JP6959252B2 (fr) |
| CN (1) | CN108884068B (fr) |
| MA (1) | MA43753A (fr) |
| WO (1) | WO2017163078A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112707893B (zh) | 2015-03-30 | 2023-10-31 | 特殊治疗有限公司 | 作为usp30抑制剂的1-氰基吡咯烷化合物 |
| WO2017009650A1 (fr) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3642196B1 (fr) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub |
| EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
| GB2571731A (en) * | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN112513036B (zh) | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| JP7434285B2 (ja) * | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| AU2019356011A1 (en) | 2018-10-05 | 2021-04-01 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
| CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| KR20220045954A (ko) | 2019-07-11 | 2022-04-13 | 이스케이프 바이오, 인크. | Lrrk2 억제제들로서의 인다졸들 및 아자인다졸들 |
| GB201912674D0 (en) * | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CA3171349A1 (fr) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines ayant une activite en tant qu'inhibiteurs de l'usp30 |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| JP2023529570A (ja) | 2020-06-04 | 2023-07-11 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
| CN115836073B (zh) | 2020-06-08 | 2024-08-27 | 特殊治疗有限公司 | 用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| EP4441044A1 (fr) | 2021-12-01 | 2024-10-09 | Mission Therapeutics Limited | N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30 |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| AU2001256981A1 (en) | 2000-04-06 | 2001-10-23 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| RU2662443C2 (ru) | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
| AU2013340345B2 (en) | 2012-11-02 | 2016-10-27 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| US9738648B2 (en) | 2013-07-31 | 2017-08-22 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof |
| KR20160063366A (ko) * | 2013-10-21 | 2016-06-03 | 메르크 파텐트 게엠베하 | Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도 |
| GB201404987D0 (en) | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| WO2015157955A1 (fr) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (fr) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| US9688629B2 (en) | 2014-10-24 | 2017-06-27 | Bristol-Myers Squibb Company | Indole carboxamide compounds |
| CN112707893B (zh) * | 2015-03-30 | 2023-10-31 | 特殊治疗有限公司 | 作为usp30抑制剂的1-氰基吡咯烷化合物 |
| WO2016192074A1 (fr) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Inhibiteurs de la btk |
| WO2017009650A1 (fr) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| WO2017123695A1 (fr) * | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Utilisation d'isoquinolones comme inhibiteurs de btk |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017172989A1 (fr) | 2016-03-30 | 2017-10-05 | Thorpe Steven Brandon | Promédicaments d'amidoxine inhibiteurs de la sphingosine kinase |
| CN111153906B (zh) | 2016-05-16 | 2020-09-11 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
| WO2017198050A1 (fr) | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | Dérivé de 5-aminopyrazole carboxamide en tant qu'inhibiteur de la btk, son procédé de préparation et composition pharmaceutique associée |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2017
- 2017-03-23 MA MA043753A patent/MA43753A/fr unknown
- 2017-03-23 JP JP2018549534A patent/JP6959252B2/ja active Active
- 2017-03-23 US US16/087,515 patent/US11352339B2/en active Active
- 2017-03-23 EP EP17714540.6A patent/EP3433246B1/fr active Active
- 2017-03-23 CN CN201780018998.XA patent/CN108884068B/zh active Active
- 2017-03-23 WO PCT/GB2017/050830 patent/WO2017163078A1/fr active Application Filing
-
2022
- 2022-02-18 US US17/674,943 patent/US11945797B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3433246A1 (fr) | 2019-01-30 |
| US20200331888A1 (en) | 2020-10-22 |
| US11945797B2 (en) | 2024-04-02 |
| WO2017163078A1 (fr) | 2017-09-28 |
| CN108884068B (zh) | 2021-02-26 |
| JP6959252B2 (ja) | 2021-11-02 |
| EP3433246B1 (fr) | 2022-05-04 |
| JP2019513135A (ja) | 2019-05-23 |
| WO2017163078A8 (fr) | 2017-12-28 |
| US20220177451A1 (en) | 2022-06-09 |
| CN108884068A (zh) | 2018-11-23 |
| US11352339B2 (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43753A (fr) | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu | |
| FR24C1016I1 (fr) | Inhibiteurs de ret | |
| MA45591A (fr) | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs | |
| CY2024003I1 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| CL2018002892A1 (es) | Composiciones de conjugado de ácido nucleico dirigido. | |
| MA45646A (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
| MA41251A (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| MA45116A (fr) | Composés hétérocycliques comme immunomodulateurs | |
| MA52546A (fr) | Compositions ciblées | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3324977T3 (da) | Benzodiazepinderivater som rsv-inhibitorer | |
| DK3356345T3 (da) | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| MA41677A (fr) | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| MA43761A (fr) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj | |
| MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
| HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
| DK3137437T3 (da) | Mikroindkapslet nitrifikationsinhibitorsammensætning |